Alembic Pharmaceuticals Limited

rs,

: 4th November, 2025 To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 533573 To, The Manager, Listing Department,

INR 19.10

tance. Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY26 2 Quarterly Snapshot Revenue INR 19.10 Bn +16% YoY EBIDTA INR 3.24 Bn EBIDTA Margin ~17% +26% YoY Key Highlights India Branded Busines

16%

Pharmaceuticals Ltd. Investor Presentation Q2 FY26 2 Quarterly Snapshot Revenue INR 19.10 Bn +16% YoY EBIDTA INR 3.24 Bn EBIDTA Margin ~17% +26% YoY Key Highlights India Branded Business Achie

INR 3.24

Ltd. Investor Presentation Q2 FY26 2 Quarterly Snapshot Revenue INR 19.10 Bn +16% YoY EBIDTA INR 3.24 Bn EBIDTA Margin ~17% +26% YoY Key Highlights India Branded Business Achieved a 5% YoY growth wi

17%

n Q2 FY26 2 Quarterly Snapshot Revenue INR 19.10 Bn +16% YoY EBIDTA INR 3.24 Bn EBIDTA Margin ~17% +26% YoY Key Highlights India Branded Business Achieved a 5% YoY growth with quarterly revenues

26%

Y26 2 Quarterly Snapshot Revenue INR 19.10 Bn +16% YoY EBIDTA INR 3.24 Bn EBIDTA Margin ~17% +26% YoY Key Highlights India Branded Business Achieved a 5% YoY growth with quarterly revenues of IN

5%

EBIDTA INR 3.24 Bn EBIDTA Margin ~17% +26% YoY Key Highlights India Branded Business Achieved a 5% YoY growth with quarterly revenues of INR 6.39 billion. US Generics Reported a 21% YoY increase d

INR 6.39 billion

6% YoY Key Highlights India Branded Business Achieved a 5% YoY growth with quarterly revenues of INR 6.39 billion. US Generics Reported a 21% YoY increase driven by key product launches and market share gains

21%

ess Achieved a 5% YoY growth with quarterly revenues of INR 6.39 billion. US Generics Reported a 21% YoY increase driven by key product launches and market share gains in select therapies. Ex-US G

10%

driven by key product launches and market share gains in select therapies. Ex-US Generics R&D 10% of revenue +41% YoY and enhancing market coverage. Reported a 31% growth YoY. In Ex-US, focus re

41%

oduct launches and market share gains in select therapies. Ex-US Generics R&D 10% of revenue +41% YoY and enhancing market coverage. Reported a 31% growth YoY. In Ex-US, focus remains on expandin

31%

erapies. Ex-US Generics R&D 10% of revenue +41% YoY and enhancing market coverage. Reported a 31% growth YoY. In Ex-US, focus remains on expanding offerings Net Profit INR 1.85 Bn Net Profit Mar